Redlining and time to viral suppression among persons with HIV

JAMA Internal Medicine

2024-09-30

(Press-News.org) About The Study: The findings of this study suggest the enduring effects of systemic racism on present-day health outcomes among persons with HIV. Regardless of their neighborhood’s contemporary level of gentrification, individuals diagnosed with HIV while living in historically redlined neighborhoods may experience a significantly longer time to viral suppression.

Corresponding Author: To contact the corresponding author, John R. Bassler, MS, email jbassle1@uab.edu.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamainternmed.2024.5003)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.5003?guestAccessKey=af8ef8f8-353c-4041-8c01-1191e0016ddf&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=093024

END

ELSE PRESS RELEASES FROM THIS DATE:

Rare diseases in Europe: Pioneering a new era through research, innovation, and advanced training, with the launch of the first European academic degree for research on rare disease

2024-09-30

Rare diseases, which affect 30 million people across Europe, are entering a new phase in diagnosis and treatment. Key initiatives include the creation of a European registry dedicated to rare diseases and the launch of Europe’s first postgraduate specialization program with academic credit recognition (a second-level master’s degree). This joint degree, offered in collaboration with various European universities, aims to train professionals with expertise in rare disease research. The team is coordinated by Professor Wanda Lattanzi, Associate Professor of Cellular ...

Expert panel calls for nutrition competencies in US medical education

2024-09-30

Embargoed for release: Monday, September 30, 11:00 AM ET Key points: There are no nationally required nutrition competencies within medical education in the U.S. In that context, researchers surveyed a professionally diverse panel of medical and nutrition experts to reach a consensus on proposed nutrition competencies for medical students and physician trainees, as well as recommendations for how to evaluate them. The proposed competencies directly respond to Congress’ bipartisan resolution H. Res. 1118, which calls for “meaningful physician ...

NCSA, Google work together in Alaska as part of Permafrost Discovery Gateway

2024-09-30

Earlier this summer, members of the National Center for Supercomputing Applications traveled to Alaska as part of their continued work with the Permafrost Discovery Gateway, a project led by the Woodwell Climate Research Center using artificial intelligence (AI) and machine learning (ML) in tracking Arctic permafrost thaw. NCSA’s Associate Director for Software Kenton McHenry and Research Software Engineer Todd Nicholson visited Fairbanks, Alaska along with 12 Google.org fellows to see first hand the melting permafrost and the impacts to those that live there. “I have seen ...

The world’s top cancer experts, entrepreneurs, and advocates to join the National Foundation for Cancer Research on October 18th, 2024, in Washington, DC, at the National Press Club

2024-09-30

Rockville, MD. (September 30, 2024) – The 2024 Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship, co-hosted by the National Foundation for Cancer Research (NFCR) and AIM-HI Accelerator Fund, will be held on October 18th at the National Press Club in Washington, DC. This is the one event each year where key leaders from the entire cancer research and patient care ecosystem come together under one roof to share critical discoveries and ideas from all areas of cancer research, drug development, and patient care. This is where many innovative ...

Cardiac myosin inhibition in heart failure with normal and supranormal ejection fraction

2024-09-30

About The Study: In an open-label trial in patients with heart failure with preserved ejection fraction with left ventricular ejection fraction of 60% or greater, mavacamten, a cardiac myosin inhibitor, was associated with improvements in biomarkers of cardiac wall stress and injury, with no sustained reductions in left ventricular ejection fraction observed. Corresponding Authors: To contact the corresponding authors, email Sanjiv J. Shah, MD, (sanjiv.shah@northwestern.edu) and Scott ...

Amy Vandiver, MD, PhD, of UCLA receives the 2024 Sagol Network GerOmic Award for Junior Faculty

2024-09-30

NEW YORK — The American Federation for Aging Research (AFAR) is pleased to announce the recipient of the 2024 Sagol Network GerOmic Award for Junior Faculty: Amy Vandiver, MD, PhD, Clinical Instructor Clinician-Investigator Track, University of California Los Angeles. Established in 2020, the Sagol Network GerOmic Award for Junior Faculty is a one- to two-year award given to junior faculty (MDs and PhDs) to conduct aging-related Omics (GerOmics) research. Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, ...

Post-mastectomy radiation therapy can be shortened by nearly half for patients planning breast reconstruction

2024-09-30

WASHINGTON, September 30, 2024 — An accelerated course of radiation therapy does not increase complications for patients who undergo breast reconstruction following a mastectomy, new research shows. Findings of the large, phase III RT CHARM trial (Alliance A221505) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting. While radiation therapy following mastectomy to remove breast cancer is known to improve survival rates for certain patients who are at higher risk of recurrence, RT CHARM is the first multi-institutional international study to show that a shorter course ...

IMRT and proton therapy offer equally high quality of life and tumor control for people with prostate cancer

2024-09-30

WASHINGTON, September 30, 2024 — People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy — proton beam therapy or intensity modulated radiation therapy (IMRT) — achieved equally high rates of tumor control with no differences in patient-reported quality of life, according to a first-of-its-kind phase III clinical trial comparing the two technologies. Findings of the PARTIQoL trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting. “We tested two contemporary, advanced forms of external ...

Timing matters when adding immunotherapy to chemoradiation for patients with limited-stage small cell lung cancer

2024-09-30

WASHINGTON, September 30, 2024 — People with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time, new research finds. The results suggest that the timing of when immunotherapy is given plays a key role in its ability to extend survival. Findings of the multi-institutional phase III trial, which also found that twice-daily radiation treatments offer greater survival benefits than once-daily treatment, will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting. The ...

Existing standard chemoradiation superior to deintensification approaches for HPV-related oropharyngeal cancer

2024-09-30

WASHINGTON, September 30, 2024 — Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to prevent long-term side effects halted a large, randomized phase II/III trial after patients in the control arm reached a record high, two-year progression-free survival rate of 98%. De-intensified treatments involving a lower radiation dose and immunotherapy in place of chemotherapy did not perform as well as the more rigorous chemoradiation approach. Findings of the NRG Oncology HN005 trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual ...

In recognition of World AIDS Day 2025, Gregory Folkers and Anthony Fauci reflect on progress made in antiretroviral treatments and prevention of HIV/AIDS, highlighting promising therapeutic developmen

Redlining and time to viral suppression among persons with HIV

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: